在阿尔茨海默氏病中,中叶的快速进展的缩
K A Jobst1, A D Smith, M Szatmari
1University Department of Pharmacology, Radcliffe Infirmary, Oxford, UK.
Lancet (London, England)
|April 2, 1994
概括
阿尔茨海默病每年导致中叶缩率为15.1%,明显超过正常衰老率 (1.5%). 这表明阿尔茨海默病是一种独特的疾病过程,而不是加速衰老.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
背景情况:
- 阿尔茨海默病 (AD) 的特点是神经元损失和中叶的病理变化.
- 了解AD中大脑缩的速度对于将其与正常衰老区分开来至关重要.
研究的目的:
- 量化中部叶缩的速度在确诊阿尔茨海默病的患者.
- 为了比较阿尔茨海默病患者的缩率与健康的老年人.
主要方法:
- 用每年一次的叶导向计算机断层扫描 (CT) 扫描来测量缩.
- 这项研究包括了20名经组织病理学确认的阿尔茨海默氏病患者和47名健康对照.
主要成果:
- 患有阿尔茨海默氏症的患者平均每年中叶缩率为15.1%.
- 健康衰老对照显示,每年缩率显著降低,为1.5%.
结论:
- 阿尔茨海默病中过度的中间叶缩表明了一个独特的病理过程.
- 阿尔茨海默病可能是一种独特的疾病过程,而不是正常衰老的加速.
相关概念视频
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...


